To enhance our understanding of the autosomal recessive limb-girdle muscular dystrophy (LGMD), patients from six genetically distinct forms (LGMD2A to LGMD2F) were studied with antibodies directed against four sarcoglycan subunits (α-, β-, γ-, δ-SG), dystrophin, β-dystroglycan (β-DG) and merosin. All patients with LGMD2A and 2B had a mild clinical course while those with a primary sarcoglycan mutation (LGMD2C to 2F) had a range of clinical severity. Dystrophin and merosin immunofluorescence pattern was positive in patients with all six AR LGMDs. The majority of patients with a severe Duchenne-like phenotype presented total absence of the SG complex. However, some exceptions were found in 13q linked patients, indicating that the presence of a certain labelling for components of the SG may not be prognostic for a milder phenotype. The observation that the primary absence of α-SG results in the total absence of β-and δ-SG but not of γ-SG suggests that the α-, β-and δ-subunits of sarcoglycan may be more closely associated. A secondary reduction in dystrophin amount was seen in patients with primary sarcoglycan mutations, which was most marked in patients with primary β-, γ-and δ-SG deficiencies. In contrast, β-DG staining was retained in all patients, suggesting that the association between SG and DG subcomplexes is not so strong. Based on the above findings, we have refined the model for the interaction among the known glycoproteins of the sarcoglycan complex, within the DGC.
INTRODUCTION
The autosomal recessive limb-girdle muscular dystrophies (ARLGMDs) include a heterogeneous group of progressive disorders mainly affecting the pelvic and shoulder girdle musculature. The clinical course is characterized by great variability, ranging from severe forms with onset in the first decade and rapid progression, resembling Xp21 Duchenne dystrophy (DMD), to milder forms with later onset and slower progression resembling Xp21 Becker muscular dystrophy or BMD (1, 2) . The severe forms are also designated as severe childhood autosomal recessive muscular dystrophy (SCARMD) or Duchenne-like muscular dystrophy (DLMD). The cloning of the DMD/BMD gene and the identification of its muscle protein product, dystrophin, which is defective (absent or abnormal) in DMD and BMD (3, 4) , opened a new era in our understanding of muscular dystrophies.
Dystrophin is a rod-shaped subsarcolemmal protein associated with several proteins and glycoproteins to form the dystrophinglycoprotein complex (DGC) (5, 6) . The DGC can be dissociated into at least two main subcomplexes: the dystroglycan and the sarcoglycan complexes (7) . The dystroglycan is composed by α-DG and β-DG (previously known as 156DAG and 43DAG/A3a). α-DG is extracellular and binds to merosin, a laminin subunit in the basal lamina (BL), while β-DG is a transmembrane protein which binds to α-DG extracellularly and to the cysteine-rich and C-terminal domains of dystrophin within the cell (8) . The sarcoglycan subcomplex is composed of at least four transmembrane glycoproteins: a 50 kDa (A2, 50DAG, α-SG), a 43 kDa (A3b, 43DAG, β-SG), a 35 kDa (A4, 35DAG, γ-SG) and the recently characterized 35 kDa (δ-SG). At least one additional 25 kDa hydrophobic protein has been biochemically characterized as part of the DGC (7).
This DGC complex forms a bridge across the muscle membrane, between the inner cytoskeleton and the BL and may stabilize the sarcolemma and protect muscle fibers from long-term contractioninduced damage and necrosis. It has been observed that the primary deficiency of dystrophin in DMD leads to a secondary deficiency of members of the DGC, implying that dystrophin is necessary for the maintenance of the complex (9, 10) . The phenotype similarity between LGMDs and DMD/BMD led to the suggestion that the genes which code for proteins of the DGC may have a role in
LGMDs.
LGMD2A was mapped to 15q15 (11) and subsequently, mutations in the proteolytic enzyme calpain-3 were found associated with LGMD2A (12) . A second gene, which results in a similar milder phenotype, (LGMD2B), was localized at 2p13 (13) (14) (15) , but its product is still unknown. The critical region has now been restricted within a PAC (16) .
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A third AR-LGMD was mapped to 13q12 in families from North Africa with a severe DMD-like phenotype and classified as LGMD2C (17) . As these patients were characteristically deficient for adhalin (50 kDa, α-SG) (18, 19) , it was predicted that the 13q gene may encode this protein. However, the adhalin gene (α-SG) was cloned and mapped to 17q21 (20, 21) and pathogenic mutations in the α-SG gene were identified in families with severe and mild AR LGMD (22, 23) . These cases were designated as LGMD2D.
Last year, Noguchi et al. (24) demonstrated that the LGMD2C gene encodes γ-SG and that the deficiency of α-SG previously detected in 13q patients was a secondary effect of the γ-SG gene mutation.
The fifth form of LGMD (2E) is due to mutations of the β-sarcoglycan gene (β-SG) at 4q12 (25, 26) . It has been observed that according to the mutation, 4q-affected patients may show a severe course (25) or a milder phenotype (26) .
More recently, a sixth form of severe AR-LGMD (LGMD2F) was mapped in two Brazilian families, to 5q33-34 (27) while a novel component of the sarcoglycan complex, δ-sarcoglycan (δ-SG) was found to map to the same region (28) . Finally, it has been demonstrated that the LGMD2F gene encodes δ-SG (29) .
From genetic analysis, it is clear that the SG complex is required for normal muscle physiology. However, the functions and the specific role of each component of the SG complex remains obscure. Interestingly, mutation analysis in Brazilian Table 1 ) as compared with myosin content on muscle extract (M).
LGMD2C and 2D patients have shown that the same mutation is associated with both mild and severe phenotypes (23, 30) . In addition, mutation analysis of the sarcoglycan genes has suggested that usually missense mutations are associated with a milder phenotype while truncating mutations tend to produce a more severe course (22, (24) (25) (26) . However, clear exceptions to this generalization have been seen (30, 31) . So, protein studies and genotype/phenotype correlations in patients suffering from the different LGMDs, chiefly those with a milder course, may be effective to improve our understanding of the manifold protein interactions and the pathogenesis of the muscle damage.
We have studied patients affected with the six autosomal recessive forms of limb-girdle muscular dystrophies in the Brazilian population and analyzed the status of the four sarcoglycan glycoproteins, dystrophin, β-DG and merosin, compared with their clinical course.
RESULTS

LGMD2A and LGMD2B
All patients linked to 15q (LGMD2A) and 2p (LGMD2B) presented with a mild phenotype, similar to the previously described clinical course (16) . Muscle biopsy showed a positive immunofluorescence (IF) pattern with antibodies directed at each of the four known sarcoglycan proteins (Fig. 1) .
LGMD2C
All patients linked to 13q (LGMD2C), despite various phenotypes, showed a complete absence of γ-SG. However, a variable positive pattern for α-, β-and δ-SG was observed in all of them, and did not correlate with the severity of the clinical course. In addition, dystrophin Western blot (WB) showed a reduced quantity in all patients (Table 1, Fig. 2 ). Table 1 as (d).
LGMD2D
One severely affected patient linked to 17q (no. 26, Table 1 ), showed a total absence of the whole SG complex. Interestingly, other more mildly affected LGMD2D patients, with the same mutation (Arg77Cys) showed positive labelling for γ-SG yet complete absence of the other SG proteins (Fig. 1) . In addition, WB showed a reduced amount of dystrophin in the severely affected patient but normal amounts in the milder cases (Fig. 2 ).
LGMD2E and LGMD2F
In the patients linked to 4q (LGMD2E) and 5q (LGMD2F), all severely affected, no trace of the four sarcoglycan proteins was detected (Fig. 1) . WB analysis showed a reduction in dystrophin quantity (Fig. 2) .
For all AR LGMD patients, dystrophin IF pattern confirmed the WB results: positive labelling was seen in all patients and some patchy labelling was observed in those with a severe phenotype, probably due to the great extent of muscle degeneration. Merosin IF pattern showed a positive labelling in all cases, while β-DG, although positive in all patients, presented a more discontinuous and weak pattern in some of the severely affected ones (Fig. 3 and Table 1 ).
DISCUSSION
In the last 2 years, three genes (at 13q, 17q and 4q) have been identified to encode glycoproteins of the SG subcomplex (20, 21, (24) (25) (26) . Earlier this year, our group has identified an additional locus responsible for AR-LGMD at 5q33-34 (27), Figure 4 . The refined proposed model: γ-SG is more intimately linked to dystrophin (although other still unknown protein (s) could mediate this interaction); α-, β-and δ-are maintained together and may link γ-SG to β-DG. This model explains how a primary α-SG deficiency may be associated with a mild phenotype, as despite the consequent deficiency of β-SG and δ-SG, the linkage between dystrophin and the basal lamina would occur through γ-SG and β-DG.
which was subsequently demonstrated to code for a novel component of the sarcoglycan complex, δ-sarcoglycan (28,29). The LGMD2C, 2D, 2E and 2F, may have a more severe phenotype, resembling Duchenne muscular dystrophy. These forms, collectively renamed 'sarcoglycanopathies' constitute a distinct subgroup of LGMDs with its own characteristics. On muscle biopsy a loss or deficiency of the whole SG subcomplex has been noted, suggesting that a primary defect in one glycoprotein results in secondary deficiency of the others components (20, 22, (24) (25) (26) 29, 37 ) (see also present data).
In contrast, the present investigation shows that mutations in the calpain gene (LGMD2A) and in LGMD2B, whose gene defect is unknown, are associated with a normal staining of dystrophin and sarcoglycan proteins.
Some correlation between IF pattern of α-SG and the type of mutation in the α-SG gene has been previously described (22) . Missense mutations seemed to be associated with partial presence of α-SG and a milder phenotype while null mutations were associated with the absence of α-SG and a more severe course. In our population, however, we observed that the same homozygous missense Arg77-Cys mutation may result in a mild or severe phenotype (23) (see also this report). Our present analysis of the components of the SG complex in muscle showed that in one severely affected patient, all four SG components were absent. However, in patients with milder phenotype, the primary deficiency of α-SG protein resulted in the total absence of β-SG and δ-SG yet γ-SG remained with a variable positive IF pattern.
We reported four families with LGMD2C and the same 521-T mutation (30) reported by Noguchi et al. (24) in Tunisian families. One family, with three affected sibs has a very mild course, in contrast to the others and those reported by Noguchi (24) . Our present analysis of the SG complex in these patients showed a total absence of γ-SG associated with a variable pattern of α-SG, β-SG and δ-SG. In the family with a mild course, the analysis of these three components of the SG complex correlates with the clinical phenotype as the oldest affected sister, with a very mild course, had a stronger IF pattern than her two younger more severely affected sibs. However, the finding of a similar IF pattern in two unrelated and more severely affected patients (Table 1, nos 19 and 20) argues against such a strict correlation.
An interesting point in this regard, however, is that for each patient, the pattern of staining of α-SG is similar to that seen for both β-SG and δ-SG, that is, either all three show a weak patchy or strong patchy IF labelling.
Finally, LGMD2E and LGMD2F patients whose mutations were previously reported (29,31) had a severe DMD-like phenotype, and showed a total absence of the four components of the SG complex and a reduction in dystrophin amount.
A reduction in dystrophin quantity is not easily detected in degenerated muscles, due to the low content of muscle proteins. Most of the reported dystrophin studies on AR-LGMD patients show normal results, but based only on IF staining (22, 24, 26, 37) . In addition to the data presented here, Matsumura et al. (18) also described one SCARMD patient with dystrophin amount reduction. This secondary event probably greatly contributes to muscular degeneration and patients weakness in AR-LGMD.
In the sarcoglycanopathies, the analysis of dystrophin amount showed a certain correlation between deficiency of γ-SG and dystrophin quantity, that is, all patients with γ-SG deficiency (primary or secondary) also showed a reduction in dystrophin amount. In addition, patients with primary α-SG deficiency, who were positive for γ-SG tended to show a normal amount of dystrophin suggesting a close relationship between dystrophin and γ-SG. This observation is also supported by the biochemical crosslinking studies of Yoshida and Ozawa (6) who suggested that A4 (γ-SG) may be directly associated with dystrophin. However, we cannot rule out the possibility that other still unknown protein(s) could mediate this interaction between dystrophin and γ-SG. On the other hand, the presence and normal distribution of the β-DG protein in patients with a total deficiency of the whole SG complex suggests that the association between these two subcomplexes may not be so strong.
In summary, the analysis of our data shows that AR-LGMD patients with a severe Duchenne-like phenotype most commonly show a total absence of the SG complex. However, one important exception is seen in 13q-linked patients, indicating that the retention of some of the SG components should not be considered prognostic for a milder phenotype. The variability in the clinical course found in patients with the same mutation, does not seem directly correlated with the primary or secondary deficiency of the proteins of the sarcoglycan complex. The observation that the primary absence of α-SG results in the total absence of β-and δ-SG but not of γ-SG suggests that α-, β-and δ-SG may be more closely associated to each other than to γ-SG within the DGC. Primary mutations that result in a marked decrease or absence of SG components are also associated with a decrease in dystrophin amount.
The observation that the same primary deficiency of a SG protein may lead to different secondary deficiencies of the other components of the SG complex, not necessarily related to the clinical course suggests that other factors, not directly related to the SG complex may contribute to the clinical variability in the sarcoglycanopathies. The pattern of maintenance or loss of α-, β-, γ-and δ-SG proteins in each primary SG deficiency may enhance our knowledge regarding the interaction of the different SG components within the complex.
Based on the above results, we have refined the model of interaction among the known glycoproteins of the sarcoglycan complex within the DGC (Fig. 4) . We suggest that α-, β-and δ-SG are more closely associated and that γ-SG may more directly interact with dystrophin.
MATERIALS AND METHODS
A total of 35 (from 21 unrelated families) LGMD patients, 24 with a mild phenotype and 11 with a severe form were included in this investigation.
The diagnosis of LGMD was established through clinical examination and course of the disease, family history, serum creatine kinase levels determinations, as well as DNA and dystrophin analysis.
The degree of functional disability was assessed through Vignos scale (32) and motor ability tests (33) . Patients were classified as mild LGMD when the onset of the disease occurred during the first or second decade and loss of ambulation after age 16; and severe DLMD when onset occurred in the first decade and patients were wheelchair-bound before age 16, or when the clinical course was as severe as Xp21 DMD.
Muscle samples were obtained through biceps biopsies (after informed consent), frozen in liquid nitrogen immediately after removal and stored at -70_C until use.
Dystrophin was analyzed in all patients by IF and WB with the rabbit polyclonal N-terminal 303-8 (kindly provided by J.
Chamberlain) and C-terminal monoclonal Dy8/6C5 antibodies (34), as described elsewhere (35, 36) .
The dystrophin amount on WB was estimated through densitometric analysis, using a dual-wave-length flying spot scanner, Shimadzu CS-9000. Each patient's band was compared with the adjacent normal control and corrected for the myosin content on the muscle extract viewed in the Ponceau pre-stained blot.
Immunohistochemical staining of frozen sections was done using double labelling reactions for dystrophin + γ-SG, α-SG + β-SG; γ-SG + δ-SG.
The following anti-sarcoglycans antibodies were used: α-SG, monoclonal Ad1/20A6 (22); β-SG, rabbit polyclonal antibody (31); γ-SG, rabbit polyclonal antibody (30) and monoclonal 35DAG/21B5 (37); δ-SG, rabbit polyclonal raised against a glutathione S-transferase (GST)-δ-sarcoglycan fusion protein (28); β-DG, monoclonal 43DAG/8D5 (38); Merosin, antihuman Merosin monoclonal antibody Ascites (Gibco).
The assignment of each family to a specific loci was performed through linkage analysis and screening for mutations. It was considered that a family was likely to be linked to a candidate locus if no recombinants were identified using the closest informative marker for the region tested. In families in which the maximum positive lod score was lower than 2.0, it was also verified if recombinants (or negative LOD scores) were detected with markers from the other candidate loci. The following families have been reported previously: 15q LGMD-2A (39, 40) ; 2p LGMD-2B (40), 13q LGMD-2C (30, 40) ; 17q LGMD-2D (23, 40) ; for 4q LGMD-2E (31), 5q LGMD-2F (27, 28) .
